Moderna's Hidden Heartache: A New Study Exposes Widespread Vascular Damage, By Mrs (Dr) Abigail Knight (Florida)

When you get a vaccine, the pitch is simple: a quick jab for protection, side effects mild and fleeting. But what if your arteries are silently protesting, stiffening and straining in ways your doctor's stethoscope can't hear? A groundbreaking peer-reviewed study from Taipei Medical University, published in the European Journal of Pharmacology on October 17, 2025, shatters that complacency. Researchers found that 91% of recipients of Moderna's mRNA-1273 vaccine (Spikevax) developed measurable cardiovascular side effects, subtle but significant arterial dysfunction, within just one week of injection. Using cutting-edge spectral analysis of the radial pulse wave, the team detected objective changes in vascular elasticity and blood flow dynamics, akin to early signs of hypertension or endothelial stress. These aren't anecdotal complaints; they're quantifiable shifts that persist beyond the "transient" label Moderna slaps on its risks. As Nicolas Hulscher, MPH, astutely notes, even if you feel fine post-shot, your arteries might beg to differ. This essay dives into Moderna's own problems, its track record of cardiac red flags, and argues this study is a wake-up call, not a fluke, exposing how mRNA tech's promise has morphed into a vascular nightmare.

The Science: Peering into the Pulse

The study's methods are elegantly precise, a far cry from the blunt instruments of routine checkups. Involving 203 healthy adults, researchers captured radial pulse waves, those faint pressure ripples from each heartbeat, before and 7 ± 3 days after mRNA-1273 vaccination. Employing Fourier analysis, they decomposed these waves into harmonic components, much like tuning a symphony into individual notes. Key metrics included:

Amplitude (Cn): Measures arterial expansion strength per beat, reduced Cn signals stiffening vessels.

Phase (Pn): Gauges wave synchronisation along the vascular tree, shifts indicate mismatched elasticity.

Variability (CVn): Tracks cardiovascular regulation stability, higher variability hints at stress.

Pre-vaccination baselines were normal across the board, ruling out confounders. Post-jab? Statistically significant drops in Cn and Pn in those reporting symptoms, with 185 of 203 participants (91%) logging cardiac (e.g., palpitations), vascular (e.g., dizziness), or combined issues. These alterations screamed "dysfunction": increased stiffness, reduced elasticity, and altered hemodynamics, hallmarks of endothelial inflammation. Remarkably, standard tests like ECGs, blood panels, and chest X-rays stayed clean for many, underscoring the subclinical stealth of these effects. The authors pinpoint spike protein as the culprit: It triggers vessel-wall inflammation, platelet clumping, and autoimmune mimicry, creating a "local mismatch in vascular elastic properties." In plain terms, Moderna's brew doesn't just poke the immune system, it pokes holes in your pipes.

This non-invasive tool, pulse wave analysis, outshines ECGs for early detection, offering a roadmap for monitoring mRNA risks in real time. Moderna's silence on such metrics? Telling.

Moderna's Own Problems: A Pattern of Cardiac Cover-Ups

This Taipei study doesn't emerge in isolation; it's the latest indictment in Moderna's litany of heart-related woes. Since mRNA-1273's 2020 emergency nod, signals have piled up like arterial plaque. A 2023 pharmacovigilance dive into 252 million recipients unearthed 3,017 myocarditis/myopericarditis cases, clustered in young males post-dose 2, with onset peaking at day 7. Rates spiked 40-fold in 16- to 17-year-old boys per Israeli data, yet Moderna downplayed it as "mild." Fast-forward to 2025: A Swiss cohort of 777 booster recipients clocked myocardial injury in 2.8%, transient troponin leaks signalling heart muscle damage, disproportionately in women, flipping the "young male" script.

Lab work echoes the alarm. A 2024 rat cardiomyocyte study exposed mRNA-1273 to ventricular cells: After 48 hours, spike expression triggered arrhythmic contractions and erratic calcium transients via ryanodine receptor sabotage, pure chaos in the heart's electrical grid. Earlier case series from 2022 detailed acute myocarditis in eight young adults post-mRNA-1273, with symptoms erupting days after dosing, echoing the Taipei timeline. CDC's 2022 analysis? Myocarditis risk post-vax pales against infection's fury but ignores cumulative boosters and long-haul subclinical hits like vascular stiffness.

Moderna's playbook? Deflect and dose. Despite these flags, the company pushes annual shots, with 2025 trials blending mRNA-1273 variants without spike tweaks for heart safety. Their global database buries signals in "expected" noise, while independent probes, like Taipei's, illuminate the shadows. It's not conspiracy; it's consistency. Spike protein, engineered for potency, doesn't discriminate: It inflames endothelium indiscriminately, from overt myocarditis to silent stiffness. Moderna's "own problems" aren't outliers, they're the operating system.

Implications: Cumulative Damage in the Shadows

The Taipei paper's genius lies in its subtlety: 91% isn't hyperbole; it's a subclinical epidemic, where "no symptoms" masks measurable menace. Standard diagnostics miss this, troponins stay flat, ECGs beep steadily, yet arteries betray the truth, hinting at hypertension precursors or clot risks down the line. For the booster brigade, repeated spikes could compound: Imagine vascular wear like tire tread on a racetrack, fraying with each lap. Hulscher's right, cumulative exposure amplifies, potentially seeding chronic heart disease in the vaccinated young.

Broader ripple? Trust erosion. As mRNA pivots to flu, cancer, even heart therapies (irony noted), unchecked cardiac baggage stalls progress. Pulse analysis emerges as a hero: Cheap, non-invasive, it could screen pre-booster or flag at-risk arms. But will regulators mandate it? Moderna's lobby says no, better to tout "safe and effective" without asterisks.

Conclusion: Time to Pump the Brakes on Moderna's Heart Game

Nicolas Hulscher's spotlight on this Taipei triumph cuts through the noise: Moderna's mRNA-1273 isn't just a jab, it's a vascular disruptor, hitting 91% with stealthy side effects that linger like a bad hangover. From subclinical stiffness to outright myocarditis, the company's own data and independents alike paint a portrait of profit over precaution. We've normalised "rare" risks while ignoring the pulse beneath, literally. The fix? Demand spike redesigns, pulse-screen mandates, and transparency that doesn't require PubMed dives. Until then, Moderna's problems are ours: A heart under siege, one shot at a time. Listen to your arteries, they're trying to tell you something.

https://www.thefocalpoints.com/p/new-study-91-of-moderna-mrna-shot